Scarica l'app Stockscreener
34.00
3.76%
-1.33
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Cogent Biosciences Inc Borsa (COGT) Ultime notizie
Is Cogent Biosciences (COGT) one of the best multibagger stocks to buy according to billionaires? - MSN
Is Cogent Biosciences (COGT) One of the Best Multibagger Stocks to Buy According to Billionaires? - Insider Monkey
Cogent Biosciences Touts Bezuclastinib Pivotal Wins, Eyes Up to Three FDA Filings and U.S. Launches - Yahoo Finance
Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned - AOL.com
(COGT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Cogent Biosciences (COGT) Valuation Check After New SUMMIT Trial Results For Bezuclastinib - Sahm
Will Cogent Biosciences Inc benefit from AI trends2025 Top Decliners & Real-Time Price Movement Reports - baoquankhu1.vn
JPMorgan raises Cogent Biosciences (COGT) PT to $67 on sector model update - MSN
Cogent Biosciences (COGT) advances bezuclastinib-sunitinib combination with breakthrough therapy designation (BTD) - MSN
Vanguard Group Inc. Has $111.40 Million Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
COGT Earnings History & Surprises | EPS & Revenue Results | COGENT BIOSCIENCES INC (NASDAQ:COGT) - ChartMill
Rafferty Asset Management LLC Purchases 57,139 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences slips after upsized $200 mln equity offering - TradingView
Cogent Biosciences: Trio Of Approvals Beckon For Lead DrugStill Bullish (NASDAQ:COGT) - Seeking Alpha
A Look At Cogent Biosciences (COGT) Valuation After Recent Share Price Volatility - Yahoo Finance
Bezuclastinib SUMMIT Data Reframe Cogent Biosciences Mastocytosis Opportunity - Yahoo Finance
Cogent Biosciences (COGT) Reveals Promising Results in Latest Be - GuruFocus
Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval - Insider Monkey
Price-Driven Insight from (COGT) for Rule-Based Strategy - Stock Traders Daily
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting - Investing News Network
Cogent Biosciences Reports Promising 48-Week Results for Bezuclastinib in NonAdvanced Systemic Mastocytosis Patients - Quiver Quantitative
Cogent Biosciences Highlights Additional Data with Six - GlobeNewswire
A Look At Cogent Biosciences (COGT) Valuation After A Strong One Year Shareholder Return - simplywall.st
Cogent Biosciences, Inc. (COGT) - DirectorsTalk Interviews
Analyst Bullish on Cogent (COGT) Amid Expected Drug Approval - Finviz
How Do Cogent Biosciences’ Growing Losses and ESOP Shelf Shape Its Capital Strategy Narrative (COGT)? - simplywall.st
COGT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cogent Biosciences Balances Bezuclastinib Phase 3 Progress With Dilution Risk - Sahm
LifeSci Capital Remains a Buy on Cogent Biosciences (COGT) - The Globe and Mail
Cogent Biosciences, Inc. $COGT Stock Position Cut by NEOS Investment Management LLC - MarketBeat
Cogent Biosciences, Inc. (COGT) Stock Analysis: Biotechnology Innovator With 40% Upside Potential - DirectorsTalk Interviews
Quarterly Risk: What is Cogent Biosciences Incs 5 year growth outlookMarket Performance Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough - AOL.com
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million - AOL.com
Readystate Asset Management LP Takes $714,000 Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Piper Sandler raises Cogent stock price target on drug launch outlook By Investing.com - Investing.com Australia
Piper Sandler raises Cogent stock price target on drug launch outlook - Investing.com South Africa
Analysts Offer Insights on Healthcare Companies: Krystal Biotech (KRYS) and Cogent Biosciences (COGT) - The Globe and Mail
COGT Sees a Boost in Price Target and Maintained Overweight Rati - GuruFocus
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Decoding Cogent Biosciences Inc (COGT): A Strategic SWOT Insight - GuruFocus
Cogent Biosciences (NASDAQ:COGT) Progress Versus Market Expectations This Quarter - Kalkine Media
(COGT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Cogent Biosciences (COGT) Reports Strong Cash Position by Year-E - GuruFocus
Cogent Biosciences, Inc. SEC 10-K Report - TradingView
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):